Kinetics and dynamics of lorazepam during and after continuous intravenous infusion

  title={Kinetics and dynamics of lorazepam during and after continuous intravenous infusion},
  author={David J Greenblatt and Lisa L. von Moltke and Bruce L. Ehrenberg and Jerold S. Harmatz and Kathleen E. Corbett and Dean W. Wallace and RichardI. Shader},
  journal={Critical Care Medicine},
ObjectiveTo evaluate the kinetics and dynamics of lorazepam during administration as a bolus plus an infusion, using electroencephalography as a pharmacodynamic end point. MethodsNine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of a 2 &mgr;g/kg/hr zero-order infusion. The infusion was stopped after 4 hrs. Plasma lorazepam concentrations and electroencephalographic activity in the 13- to 30-Hz range were monitored for 24 hrs. ResultsThe bolus-plus… 

Kinetics and EEG Effects of Midazolam during and after 1‐Minute, 1‐Hour, and 3‐Hour Intravenous Infusions

Midazolam infusions in duration of up to 3 hours produce CNS sedation without evidence of tolerance and a kinetic‐dynamic model in which hypothetical effect‐site concentration was related to pharmacodynamic EEG effect via the sigmoid Emax model was incorporated.

Lorazepam-induced effects on silent period and corticomotor excitability

The statistical analysis of the SP S/R curves as well as the study of SPs at two SI levels revealed that lorazepam reduced SP duration when high intensity stimuli were used (>60%).

Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan

Continuous i.v. infusion of lorazepam together with BU-based conditioning regimen in 16 consecutive children, aged 1–17 years, who underwent HSCT for neuroblastoma, AML, SCID and Ewing sarcoma is used, providing a more reliable therapeutic effect.

Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia

On average, intramuscular haloperidol led to minimal prolongation of the QT interval, which is of theoretical concern in individuals with risk factors for torsade de pointes but seems unlikely to be a problem in the vast majority of patients.

In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat

Although the in vitro and in vivo characteristics of midazolam in rats incompletely parallel those in humans, the experimental model can be used to assess aspects of drug interactions having potential clinical importance.

Kinetics and Dynamics of Intravenous Adinazolam, N‐Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers

Results indicate that the benzodiazepine‐like effects occurring after adinazolam administration are mediated by mainly NDMAD, and the relation of both alprazolam and N DMAD plasma concentrations to DSST performance could be described by a modified exponential model.


Techniques for the study of drug metabolism in vitro have advanced substantially during the last decade, and now are an integral component of preclinical drug development and the link to subsequent clinical studies ofdrug metabolism and disposition.

Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

The effect that pharmaceutical formulation has on the occurrence and potential change in direction of the hysteresis loop, and the major pharmacokinetic / pharmacodynamic modeling approaches utilized to collapse and model hysteResis are detailed are detailed.



Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam.

Six healthy volunteers received a single i.v. dose of 'low dose' lorazepam (0.0225 mg/kg), 'high dose' lorazepam (0.045 mg/kg) and placebo by 1-min infusion in a double-blind three-way crossover

Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo

Electroencephalographic effects of diazepam, midazolam and placebo were indistinguishable from baseline by 6 to 8 hours, suggesting that distribution contributes importantly to terminating pharmacodynamic action.

Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding.

There is a diurnal variation in lorazepam elimination consistent with a fasting-induced increase in hepatic glucuronidation during the night, combined with the relative inactivity of the gut during this period, serves to trap the glucuronide and delay its transfer back to the systemic circulation and urine.

Chronopharmacokinetic Study with Prolonged Infusion of Midazolam

SummaryPhysiological and temporal variation in the disposition of midazolam has been reported. In order to delineate the underlying mechanisms of these alterations, we infused in 5 healthy male

Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constant.

Data from the step-infusion treatment indicate that the triazolam effect-concentration relationship after a single dose can be altered by rate of administration, and suggests intersubject variability in the rate of development of acute tolerance.

Evaluation of the development of acute tolerance to the psychomotor effects of midazolam following intravenous infusions in healthy volunteers

Tolerance develops acutely to the effects of midazolam and suggest that tolerance is dependent on both the time and extent of exposure.

Tolerance to alprazolam after intravenous bolus and continuous infusion: Psychomotor and EEG effects

The resulting tolerance model describes both DSS and SE vs. time data from the rapid‐injection and continuous‐infusion treatments and three distinct effect‐concentration curves result from the three alprazolam treatments, with successive shifts to the right as dose increases.

Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time

The EEG analysis provides objective quantitation of benzodiazepine central nervous system effects, in turn reflecting plasma levels and other clinical measures.

Clinical Pharmacokinetics of Oxazepam and Lorazepam

3-hydroxy benzodiazepine derivatives used as sedatives and anxiolytics and Oral and intramuscular lorazepam are rapidly absorbed, with systemic availability averaging 90 % or more.

Lorazepam treatment of experimental status epilepticus in the rat

It is suggested that a target serum concentration of 200 ng/ml should be effective in most cases and provide seizure protection for 24 hours following treatment and confirmed clinical reports of lorazepam's effectiveness as a treatment for SE.